Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shujun Liu

Showing results (291-300 of 315) with videos related to

Pageof 32
Sort By:
Cancer Cell|November 16, 2005
The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET proteinPaolo Neviani, Ramasamy Santhanam, Rossana Trotta, et al.
Blood|March 31, 2009
TSC-22 contributes to hematopoietic precursor cell proliferation and repopulation and is epigenetically silenced in large granular lymphocyte leukemiaJianhua Yu, Maxim Ershler, Li Yu, et al.
The Journal of Clinical Investigation|March 3, 2011
NKp46 identifies an NKT cell subset susceptible to leukemic transformation in mouse and humanJianhua Yu, Takeki Mitsui, Min Wei, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2007
Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemiaWilliam Blum, Rebecca B Klisovic, Bjoern Hackanson, et al.
The Journal of Clinical Investigation|September 19, 2006
Mll partial tandem duplication induces aberrant Hox expression in vivo via specific epigenetic alterationsAdrienne M Dorrance, Shujun Liu, Weifeng Yuan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2008
A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemiaRebecca B Klisovic, Wendy Stock, Spero Cataland, et al.
Cell Death & Disease|November 7, 2025
The RNA N<sup>6</sup>-methyladenosine methylome coordinates long non-coding RNAs to mediate cancer drug resistance by activating PI3K signalingYanhong Tan, Changli Zhou, Sicheng Bian, et al.
Blood|December 18, 2007
Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemiaShujun Liu, Zhongfa Liu, Zhiliang Xie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2010
Dose escalation of lenalidomide in relapsed or refractory acute leukemiasWilliam Blum, Rebecca B Klisovic, Heiko Becker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 13, 2005
Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activityGuido Marcucci, Wendy Stock, Guowei Dai, et al.
Pageof 32

Showing results (291-300 of 315) with videos related to

Sort By:
Pageof 32
Cancer Cell|November 16, 2005
The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET proteinPaolo Neviani, Ramasamy Santhanam, Rossana Trotta, et al.
Blood|March 31, 2009
TSC-22 contributes to hematopoietic precursor cell proliferation and repopulation and is epigenetically silenced in large granular lymphocyte leukemiaJianhua Yu, Maxim Ershler, Li Yu, et al.
The Journal of Clinical Investigation|March 3, 2011
NKp46 identifies an NKT cell subset susceptible to leukemic transformation in mouse and humanJianhua Yu, Takeki Mitsui, Min Wei, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2007
Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemiaWilliam Blum, Rebecca B Klisovic, Bjoern Hackanson, et al.
The Journal of Clinical Investigation|September 19, 2006
Mll partial tandem duplication induces aberrant Hox expression in vivo via specific epigenetic alterationsAdrienne M Dorrance, Shujun Liu, Weifeng Yuan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2008
A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemiaRebecca B Klisovic, Wendy Stock, Spero Cataland, et al.
Cell Death & Disease|November 7, 2025
The RNA N<sup>6</sup>-methyladenosine methylome coordinates long non-coding RNAs to mediate cancer drug resistance by activating PI3K signalingYanhong Tan, Changli Zhou, Sicheng Bian, et al.
Blood|December 18, 2007
Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemiaShujun Liu, Zhongfa Liu, Zhiliang Xie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2010
Dose escalation of lenalidomide in relapsed or refractory acute leukemiasWilliam Blum, Rebecca B Klisovic, Heiko Becker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 13, 2005
Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activityGuido Marcucci, Wendy Stock, Guowei Dai, et al.
Pageof 32